Home › Companies › NEVRO CORP. › 2024-2025

NEVRO CORP. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and NEVRO CORP.’s Form 8-K, filed 2025-04-02 (Item 5.07 on EDGAR). Page generated 04 October 2026.

4Reported items
149Asset managers
539Fund votes
2025-04-02Meeting date

Proxy season: 2023-2024 2024-2025

Explore NEVRO CORP. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by NEVRO CORP.

These tallies are NEVRO CORP.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2025-04-02 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

NEVRO CORP. — official shareholder meeting results, meeting held 2025-04-02
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Proposal 1: Proposal No. 1 - The Merger Proposal : To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, Inc., a Delaware corporation ("Globus"), P	28,350,441	684,453	90,808	--	--	Majority: yes
Proposal 2: Proposal No. 2 - The Merger Compensation Proposal : To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is based on or otherwise relates to the Merge	9,661,595	17,932,514	1,531,593	--	--	Majority: no

Source: NEVRO CORP., Form 8-K, filed with the SEC on 2025-04-02 — read the filing on EDGAR.

How asset managers voted at the NEVRO CORP. 2024-2025 meeting

Each item below shows how the 149 asset managers that disclosed a NEVRO CORP. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of NEVRO CORP.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is based on or otherwise relates to the Merger; and

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: no

Combines 9 wordings of this item as funds reported it.

35% Majority: no · of votes cast

FOR 35%AGAINST 65%

FOR: 9,661,595AGAINST: 17,932,514

NEVRO CORP.’s own tally for this item (“Proposal 2: Proposal No. 2 - The Merger Compensation Proposal : To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable to Nevro's named executive officers that is ba”): 9,661,595 for, 17,932,514 against, per its Form 8-K filed 2025-04-02 (Item 5.07). FOR was not more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,824,467 outstanding shares: 26% for, 47.4% against (73% of the company cast a for/against vote).

The 145 asset managers below cast 23% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.

FOR 22%AGAINST 73%

FOR: 21.6%AGAINST: 73.5%ABSTAIN: 4.9%

Largest asset managers voting on “To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or become payable ” at NEVRO CORP., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	0	4,792,530	0	Against
ArrowMark Colorado Holdings LLC	0	4,147,892	0	Against
BlackRock	333	2,617,597	0	Against
Beryl Capital Management LLC	2,393,053	0	0	For
Rock Springs Capital Management LP	0	1,848,100	0	Against
ODDO BHF ASSET MANAGEMENT SAS	0	0	1,463,800	Abstain
BALYASNY ASSET MANAGEMENT L.P.	0	969,864	0	Against
MERIDIAN FUND INC	0	917,871	0	Against
GEODE CAPITAL MANAGEMENT, LLC	0	858,241	0	Against
Fidelity	0	832,037	0	Against
State Street	730,245	7,476	0	For
Gabelli	737,250	0	0	For
DE Shaw	0	717,003	0	Against
Charles Schwab	0	624,594	0	Against
Goldman Sachs	424,692	124,090	0	For
GARDNER LEWIS ASSET MANAGEMENT L P	512,353	0	0	For
BOOTHBAY FUND MANAGEMENT, LLC	500,984	0	0	For
GDL FUND	404,178	0	0	For
T. Rowe Price	0	385,974	0	Against
Nuveen	0	369,554	0	Against
TIAA	0	350,810	0	Against
Northern Trust	0	334,489	0	Against
COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS	0	277,430	0	Against
Renaissance	0	208,760	0	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	202,608	0	Against

Showing the 25 largest of 145 asset managers. See all 145 in the interactive database.

2. To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, Inc., a Delaware corporation ("Globus"), Palmer Merger Sub Inc., a Delaware corporation and a direct wholly owned subsidiary of Globus ("Merger Sub"), and Nevro Corp., a Delaware corporation ("Nevro"), pursuant to which Merger Sub wi

EXTRAORDINARY TRANSACTIONSMajority of the votes cast: yes

Combines 3 wordings of this item as funds reported it.

98% Majority: yes · of votes cast

FOR 98%

FOR: 28,350,441AGAINST: 684,453

NEVRO CORP.’s own tally for this item (“Proposal 1: Proposal No. 1 - The Merger Proposal : To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), dated as of February 6, 2025, by and among Globus Medical, In”): 28,350,441 for, 684,453 against, per its Form 8-K filed 2025-04-02 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 37,824,467 outstanding shares: 75% for, 2% against (77% of the company cast a for/against vote).

The 46 asset managers below cast 100% of the shares they voted on this item FOR (10,080,427 for, 0 against).

FOR 99.4%

FOR: 10,080,427 (99.5%)ABSTAIN: 51,570 (0.5%)

Largest asset managers voting on “To adopt the Agreement and Plan of Merger (as it may be amended from time to time, the "Merger Agreement"), da” at NEVRO CORP., 2024-2025
Asset manager	For	Abstain	Vote
Vanguard	4,759,644	0	For
BlackRock	1,388,132	0	For
MERIDIAN FUND INC	917,871	0	For
Fidelity	829,879	0	For
GDL FUND	404,178	0	For
TIAA	350,810	0	For
Charles Schwab	312,297	0	For
Equitable	147,784	51,570	For
Gabelli	130,000	0	For
ALTSHARES TRUST	114,716	0	For
T. Rowe Price	110,564	0	For
Goldman Sachs	81,963	0	For
Dimensional	73,478	0	For
QUANTITATIVE MASTER SERIES LLC	60,601	0	For
American Century	43,272	0	For
Amplify ETF Trust	40,299	0	For
Northern Trust	35,390	0	For
Lincoln Financial	30,008	0	For
Nationwide	26,262	0	For
Invesco	23,647	0	For
Global X	21,293	0	For
Pacific Life	21,024	0	For
MASTER INVESTMENT PORTFOLIO	20,264	0	For
AIG/SunAmerica	18,112	0	For
Bridge Builder Trust	16,112	0	For

Showing the 25 largest of 46 asset managers. See all 46 in the interactive database.

3. TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF NECESSARY TO SOLICIT ADDITIONAL PROXIES IF THERE ARE INSUFFICIENT VOTES IN PERSON OR BY PROXY TO APPROVE THE PROPOSAL TO ADOPT THE MERGER AGREEMENT AT THE TIME OF THE SPECIAL MEETING.

CORPORATE GOVERNANCE

91% fund support · no official result

FOR 90%9%

The 45 asset managers below cast 91% of the shares they voted on this item FOR (9,163,293 for, 917,124 against).

FOR: 9,163,293 (90.4%)AGAINST: 917,124 (9.1%)ABSTAIN: 51,570 (0.5%)

Largest asset managers voting on “TO APPROVE THE ADJOURNMENT OF THE SPECIAL MEETING TO A LATER DATE OR DATES IF NECESSARY TO SOLICIT ADDITIONAL ” at NEVRO CORP., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	4,759,644	0	0	For
BlackRock	1,388,132	0	0	For
MERIDIAN FUND INC	917,871	0	0	For
Fidelity	67,200	762,679	0	Against
GDL FUND	404,178	0	0	For
TIAA	350,810	0	0	For
Charles Schwab	312,297	0	0	For
Equitable	147,784	0	51,570	For
Gabelli	130,000	0	0	For
ALTSHARES TRUST	114,716	0	0	For
T. Rowe Price	0	110,564	0	Against
Goldman Sachs	81,963	0	0	For
Dimensional	73,478	0	0	For
QUANTITATIVE MASTER SERIES LLC	60,601	0	0	For
American Century	43,272	0	0	For
Amplify ETF Trust	40,299	0	0	For
Northern Trust	35,390	0	0	For
Lincoln Financial	2,108	27,900	0	Against
Nationwide	26,262	0	0	For
Invesco	23,647	0	0	For
Global X	21,293	0	0	For
Pacific Life	21,024	0	0	For
MASTER INVESTMENT PORTFOLIO	20,264	0	0	For
AIG/SunAmerica	18,112	0	0	For
Bridge Builder Trust	16,112	0	0	For

Showing the 25 largest of 45 asset managers. See all 45 in the interactive database.

4. Advisory Vote on Golden Parachutes

SECTION 14A SAY-ON-PAY VOTES

0.5% fund support · no official result

AGAINST 99.5%

The 4 asset managers below cast 0.5% of the shares they voted on this item FOR (224 for, 45,746 against).

FOR: 224 (0.5%)AGAINST: 45,746 (99.5%)

Largest asset managers voting on “Advisory Vote on Golden Parachutes” at NEVRO CORP., 2024-2025
Asset manager	For	Against	Vote
ALGERT GLOBAL LLC	0	28,420	Against
JPMorgan	0	17,326	Against
Coyle Financial Counsel LLC	112	0	For
SIERRA SUMMIT ADVISORS LLC	112	0	For

Largest NEVRO CORP. shareholders voting in 2024-2025

Ranked by the number of NEVRO CORP. shares each manager voted on the most widely held ballot item of the 2024-2025 meeting, shown as a share of the 37,824,467 shares outstanding at the time of that meeting.

Top NEVRO CORP. shareholders by shares voted, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	12.67%
2	ArrowMark Colorado Holdings LLC	10.97%
3	BlackRock	6.92%
4	Beryl Capital Management LLC	6.33%
5	Rock Springs Capital Management LP	4.89%
6	ODDO BHF ASSET MANAGEMENT SAS	3.87%
7	BALYASNY ASSET MANAGEMENT L.P.	2.56%
8	MERIDIAN FUND INC	2.43%
9	GEODE CAPITAL MANAGEMENT, LLC	2.27%
10	Fidelity	2.20%

Reported NEVRO CORP. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

NEVRO CORP. beneficial owners on record for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Armistice Capital, LLC	9.88%	13G
BlackRock	7.75%	13F
Goldman Sachs	5.48%	13F
Vanguard Group	5.47%	13F
D.E. Shaw	3.31%	13F
Renaissance Technologies	3.20%	13F
Geode Capital	2.33%	13F
State Street	2.08%	13F
Morgan Stanley	1.53%	13F
Nuveen	0.98%	13F

Percentages above are of 37,824,467 shares outstanding, as reported by NEVRO CORP. on its Form 10-K dated 2024-12-31 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from NEVRO CORP.’s 10-K dated 2024-12-31. This page is a static snapshot rebuilt weekly on 04 October 2026; a live search always shows the current data.

At NEVRO CORP.'s shareholder meeting held 2025-04-02, in the 2024-2025 proxy season, 149 asset managers reported how they voted in their SEC Form N-PX filings, covering 539 separate fund positions. Their filings are grouped here into 4 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, certain compensation that will or may be paid or… — FOR was 35% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is not more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: NEVRO CORP.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2025-04-02.

NEVRO CORP. proxy season coverage: 2023-2024 · 2024-2025 (this page).